ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis
USA - NYSE:ADCT - CH0499880968 - Common Stock
3.96 USD
-0.09 (-2.22%)
4.03 USD
+0.07 (+1.77%)
Overall ADCT gets a fundamental rating of 2 out of 10. We evaluated ADCT against 531 industry peers in the Biotechnology industry. ADCT has a bad profitability rating. Also its financial health evaluation is rather negative. ADCT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ADCT had negative earnings in the past year.
ADCT had a negative operating cash flow in the past year.
In the past 5 years ADCT always reported negative net income.
In the past 5 years ADCT always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -52.85%, ADCT perfoms like the industry average, outperforming 47.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.85% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 93.37%, ADCT belongs to the top of the industry, outperforming 93.22% of the companies in the same industry.
In the last couple of years the Gross Margin of ADCT has declined.
The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADCT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADCT has been increased compared to 5 years ago.
The debt/assets ratio for ADCT is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.51, we must say that ADCT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.51, ADCT is doing worse than 65.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.51 |
ROIC/WACCN/A
WACC4.73%
2.3 Liquidity
A Current Ratio of 4.93 indicates that ADCT has no problem at all paying its short term obligations.
With a Current ratio value of 4.93, ADCT perfoms like the industry average, outperforming 55.37% of the companies in the same industry.
ADCT has a Quick Ratio of 4.66. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.66, ADCT is in line with its industry, outperforming 54.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.66 |
3. Growth
3.1 Past
ADCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.35%, which is quite impressive.
ADCT shows a small growth in Revenue. In the last year, the Revenue has grown by 1.84%.
The Revenue has been growing by 98.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)44.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)1.84%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%-11.02%
3.2 Future
ADCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.54% yearly.
ADCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.94% yearly.
EPS Next Y5.73%
EPS Next 2Y9.1%
EPS Next 3Y13.54%
EPS Next 5YN/A
Revenue Next Year6.62%
Revenue Next 2Y5.72%
Revenue Next 3Y27.81%
Revenue Next 5Y33.94%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ADCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ADCT's earnings are expected to grow with 13.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.1%
EPS Next 3Y13.54%
5. Dividend
5.1 Amount
ADCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.96
-0.09 (-2.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners59.3%
Inst Owner Change0.43%
Ins Owners5.81%
Ins Owner Change35.48%
Market Cap445.50M
Revenue(TTM)70.84M
Net Income(TTM)-169.94M
Analysts86.67
Price Target8.16 (106.06%)
Short Float %7.15%
Short Ratio6.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)12.49%
Max EPS beat(2)21.4%
EPS beat(4)3
Avg EPS beat(4)15.15%
Min EPS beat(4)-4.24%
Max EPS beat(4)30.94%
EPS beat(8)6
Avg EPS beat(8)-1.26%
EPS beat(12)6
Avg EPS beat(12)-10.49%
EPS beat(16)10
Avg EPS beat(16)0.13%
Revenue beat(2)2
Avg Revenue beat(2)15.46%
Min Revenue beat(2)3.41%
Max Revenue beat(2)27.51%
Revenue beat(4)2
Avg Revenue beat(4)4.05%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)27.51%
Revenue beat(8)3
Avg Revenue beat(8)0.74%
Revenue beat(12)5
Avg Revenue beat(12)0.65%
Revenue beat(16)8
Avg Revenue beat(16)7.74%
PT rev (1m)-3.03%
PT rev (3m)-3.03%
EPS NQ rev (1m)-2.17%
EPS NQ rev (3m)2.78%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-21.42%
Revenue NQ rev (1m)-7.16%
Revenue NQ rev (3m)-6.78%
Revenue NY rev (1m)-1.49%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.77 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.69
BVpS-1.77
TBVpS-1.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.85% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.37% | ||
| FCFM | N/A |
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 159.66% | ||
| Cap/Sales | 0.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.66 | ||
| Altman-Z | -6.51 |
F-Score2
WACC4.73%
ROIC/WACCN/A
Cap/Depr(3y)144.88%
Cap/Depr(5y)161.59%
Cap/Sales(3y)2.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y5.73%
EPS Next 2Y9.1%
EPS Next 3Y13.54%
EPS Next 5YN/A
Revenue 1Y (TTM)1.84%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%-11.02%
Revenue Next Year6.62%
Revenue Next 2Y5.72%
Revenue Next 3Y27.81%
Revenue Next 5Y33.94%
EBIT growth 1Y51.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.43%
OCF growth 3YN/A
OCF growth 5YN/A
ADC THERAPEUTICS SA / ADCT FAQ
Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?
ChartMill assigns a fundamental rating of 2 / 10 to ADCT.
What is the valuation status for ADCT stock?
ChartMill assigns a valuation rating of 0 / 10 to ADC THERAPEUTICS SA (ADCT). This can be considered as Overvalued.
Can you provide the profitability details for ADC THERAPEUTICS SA?
ADC THERAPEUTICS SA (ADCT) has a profitability rating of 1 / 10.
What is the financial health of ADC THERAPEUTICS SA (ADCT) stock?
The financial health rating of ADC THERAPEUTICS SA (ADCT) is 2 / 10.